Prosecution Insights
Last updated: October 02, 2026

Examiner: SPAINE, ROBERT FRANKLIN

Tech Center 1600 • Art Units: 1617 1655

This examiner grants 75% of resolved cases

Analysis

Robert Franklin Spaine examines applications in Tech Center 1600 and Art Unit 1617. With only 8 resolved cases, the data pool is limited but shows a high allowance rate of 75.0%. This rate suggests a favorable outlook for applicants, although the median days to allowance of 1014 indicates that the process still requires significant time. The small number of resolutions means that individual case outcomes have a large impact on these percentages.

The interview lift of 0.0% is a critical data point. It indicates that interviews have not historically improved the 75.0% allowance rate for this examiner. For practitioners, this suggests that written arguments or amendments might be more effective than verbal consultations when navigating Art Unit 1617. The 1014 days to allowance remains the primary benchmark for timeline expectations in these 8 resolved cases. Given the 75.0% allowance rate, the lack of lift suggests that cases are typically allowed on their merits or rejected despite verbal discussion. Applicants should prioritize clear written advocacy to maintain the high probability of success.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

75.0%
Allow Rate
+15.0% vs TC avg
50
Total Applications
+0.0%
Interview Lift
1014
Avg Prosecution Days
Based on 8 resolved cases, 2023–2026

Rejection Statute Breakdown

9.3%
§101 Eligibility
6.7%
§102 Novelty
45.0%
§103 Obviousness
27.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18580411 COMPOSITIONS COMPRISING CONSTITUENTS, DERIVATIVES OR EXTRACTS OF CANNABIS Final Rejection Nicoventures Trading Limited
18730928 COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, COMPRISING EXTRACELLULAR VESICLES DERIVED FROM ROSEBURIA SPP. OR BIFIDOBACTERIUM SPP. Non-Final OA KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
18705307 COMPOSITIONS SUITABLE FOR USE IN SKIN CARE Non-Final OA JOHNSON & JOHNSON CONSUMER INC.
18610473 MELTING MASSAGE BAR Non-Final OA Johnson & Johnson Consumer Inc.
18694586 FILLER COMPOSITION FOR REDUCING SKIN WRINKLES COMPRISING STEM CELL-DERIVED EXOSOMES, HYALURONIC ACID, AND BDDE AND METHOD FOR PREPARING SAME Final Rejection RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
18706991 STEM CELL PROLIFERATION PROMOTER Non-Final OA SHISEIDO COMPANY, LTD.
18688795 Prunella vulgaris extract and use thereof Non-Final OA Clariant International Ltd
18705256 COMPOSITION FROM ARONIA MELANOCARPA Non-Final OA GIVAUDAN SA
18352677 COMPOSITIONS CONTAINING KRATOM COMPOUNDS Non-Final OA CAAMTECH, INC.
17795389 PROCESS FOR OBTAINING AN AQUEOUS EXTRACT OF LAVENDER, COMPOSITIONS COMPRISING SUCH AN EXTRACT, AND THEIR COSMETIC USES Final Rejection ISP INVESTMENTS LLC.
18409817 METHODS FOR IMPROVING SLEEP QUALITY, INCREASING MITOCHONDRIAL EXPRESSION, PROMOTING CELL REPAIRING, OR FIRMING SKIN BY USING SPARASSIA CRISPA EXTRACT Final Rejection TCI CO., LTD.
18528783 METHODS FOR RESISTING SKIN AGING BY USING KIWIBERRY EXTRACT Non-Final OA TCI CO., LTD.
18560734 COSMETIC COMPOSITION, USE OF CASEARIA SYLVESTRIS, SCHINUS TEREBINTHIFOLIUS, HYMENAEA COURBARIL AND LACTOBACILLUS AND METHOD FOR THE PREVENTION AND/OR TREATMENT OF SIGNS RESULTING FROM SKIN AGING Final Rejection Natura Cosméticos S.A.
18164368 METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING Non-Final OA GOWEY RESEARCH GROUP, PLLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month